ENDRA Life Sciences (NDRA) Change in Accured Expenses (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Change in Accured Expenses for 11 consecutive years, with -$53553.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Accured Expenses fell 713.23% year-over-year to -$53553.0 in Q2 2026; TTM through Jun 2026 was $199513.0, a 127.5% increase from a year earlier, with the FY2025 full-year figure at $113287.0, up 156.97% from the prior year.
• Change in Accured Expenses was -$53553.0 for Q2 2026 at ENDRA Life Sciences, down from $79908.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $337711.0 in Q1 2024 and troughed at -$1.3 million in Q4 2023.
• A 5-year average of -$42772.7 and a median of $44320.5 in 2025 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses jumped 400.8% in 2022 and plunged 3524.36% in 2023, its largest moves.
• Over 5 years, Change in Accured Expenses stood at -$35085.0 in 2022, then sank by 3524.36% to -$1.3 million in 2023, then soared by 90.19% to -$124769.0 in 2024, then jumped by 59.98% to -$49937.0 in 2025, then fell by 7.24% to -$53553.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$53553.0 (Q2 2026), $79908.0 (Q1 2026), and -$49937.0 (Q4 2025), per Business Quant data.